Last updated: 07/31/2020 02:30:24

Single and Repeated Dose Escalation Study of GSK2838232

GSK study ID

204953

See study documents

Clinicaltrials.gov ID

NCT02795754

EudraCT ID

Not applicable

EU CT Number

Not applicable

Trial status

Study complete

Overview

Eligibility

Locations

Study documents

Results summary

Plain language summaries

Additional information

Trial overview

Official title: A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Continuation Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 with Ritonavir, in Healthy Subjects

Trial description: GSK2838232 is a Human Immunodeficiency Virus (HIV) maturation inhibitor being developed for the treatment of HIV in combination with other antiretroviral therapy (ART). The primary objectives of this study are to investigate the safety, tolerability, and pharmacokinetics (PK) of single and repeat doses of GSK2838232. This study will be a double-blind, placebo-controlled, single and repeat dose escalation study. This study will be conducted in two Parts: single escalating doses (Part 1A and 1B), and repeated escalating once daily (QD) doses for 11 days (Part 2) of GSK2838232 co-dosed with RTV. During Part 1A, single doses of GSK2838232 (as of active pharmaceutical ingredient-powder in bottle [API PiB]) 50 milligrams (mg), 100mg and 200mg will be administered with RTV. Part 1B will evaluate the relative bioavailability of single doses of crystalline active pharmaceutical ingredient (API) Immediate Release Tablet (IR) tablets versus API PiB as reference, administered with RTV. In Part 2, multiple doses of GSK2838232 will be co-administered with RTV 100mg QD for 11 days as sequential dose cohorts. Maximum duration of study participation will be approximately 10 weeks.

Primary purpose:

Treatment

Trial design:

Crossover Assignment

Masking:

Double (Participant, Investigator)

Allocation:

Randomized

Primary outcomes:

Number of participants with adverse events (AEs)

Timeframe: Approximately 10 weeks

Safety as assessed by absolute values and change from Baseline in hematology parameters –Part 1

Timeframe: Baseline (Day -1) and up to 10 weeks

Safety as assessed by absolute values and change from Baseline in hematology parameters – Part 2

Timeframe: Baseline (Day-1) and up to Day 31 for each cohort.

Safety as assessed by absolute values and change from Baseline in clinical chemistry parameters –Part 1

Timeframe: Baseline (Day -1) and up to 10 weeks

Safety as assessed by absolute values and change from Baseline in clinical chemistry parameters- Part 2

Timeframe: Baseline (Day-1) and up to Day 31 for each cohort.

Safety as assessed by absolute values and change from Baseline in urinalysis parameters-Part 1

Timeframe: Baseline (Day -1) and up to 10 weeks

Safety as assessed by absolute values and change from Baseline in urinalysis parameters-Part 2

Timeframe: Baseline (Day-1) and up to Day 31 for each cohort.

Safety as assessed by Blood pressure-Part 1

Timeframe: 10 weeks

Safety as assessed by Heart rate -Part 1

Timeframe: 10 weeks

Safety as assessed by Blood pressure-Part 2

Timeframe: 31 days in each cohort

Safety as assessed by Heart rate -Part 2

Timeframe: 31 days in each cohort

Safety as assessed by Electrocardiogram (ECG) parameters-Part 1

Timeframe: Up to 10 weeks

Safety as assessed by ECG parameters-Part 2

Timeframe: 31 days in for each cohort

Area under the concentration-time curve from time zero (pre-dose) to 24 hours (AUC[0-24]), Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC [0-inf]) in Part 1

Timeframe: Plasma samples will be collected pre-dose (within 15 minutes prior to dosing) and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose at each study visit

Apparent oral clearance (CL/F) for single dose GSK2838232 in Part 1A

Timeframe: Plasma samples will be collected pre-dose (within 15 minutes [min]prior to dosing) and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose at each study visit during Part 1A.

Area under the concentration-time curve over the dosing interval (AUC[0 tau]) for repeated dose GSK2838232 in Part 2

Timeframe: Day 1; pre-dose (within 15 min prior to dosing) and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hr post dose.On Day 11; pre-dose (within 15 min prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hr post dose

Apparent oral clearance (CL/F) for repeated dose GSK2838232 in Part 2

Timeframe: Plasma samples will be collected on Day 11; pre-dose (within 15 minutes prior to dosing) and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours post dose.

Tmax for repeated dose GSK2838232 in Part 2

Timeframe: Day 1; pre-dose (within 15 min prior to dosing) and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hr post dose. On Day 11; pre-dose (within 15 min prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96,120 and 144 hr post dose

Tlag for repeated dose GSK2838232 in Part 2

Timeframe: Day 1; pre-dose (within 15 min prior to dosing) and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hr post dose. On Day 11; pre-dose (within 15 min prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96,120 and 144 hr post dose

T1/2 for repeated dose GSK2838232 in Part 2

Timeframe: Day 1; pre-dose (within 15 min prior to dosing) and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hr post dose. On Day 11; pre-dose (within 15 min prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96,120 and 144 hr post dose

Tlast for repeated dose GSK2838232 in Part 2

Timeframe: Day 1; pre-dose (within 15 min prior to dosing) and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hr post dose. On Day 11; pre-dose (within 15 min prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96,120 and 144 hr post dose

Maximum observed concentration (Cmax) in Part 1

Concentration at 24 hours post dose (C24) in Part 1

Last measurable concentration (Clast) in Part 1

Time of occurence of Cmac (tmax) in Part 1

Lag time before observation of drug concentrations in sampled matrix (tlag) in Part 1

Terminal phase half life (t1/2) in Part 1

Time of last observed quantifiable concentration (t-last) in Part 1

Cmax of GSK2826232 in Part 2

Clast of GSK2826232 in Part 2

Concentration-time curve over the dosing interval (Ctau) of GSK2838232 in Part 2

Secondary outcomes:

AUC (0-inf) in Part 1

Cmax in Part 1

AUC(0-tau) in Part 2

Timeframe: Day 1 pre-dose; 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24 hr post dose. Days 3-10 pre-dose; Day 11; pre-dose and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hr post dose; all pre-dose within 15 min prior to dosing

Cmax in Part 2

Ctau in Part 2

Pre-dose GSK2838232 plasma concentrations on Day 2-11 in Part 2

Timeframe: Up to Day 11

Accumulation ratios (Ro) for AUC (0-tau)

Accumulation ratios (Ro) for Cmax

Accumulation ratios (Ro) for Ctau (where tau is 24 hours)

Interventions:

Drug: GSK2838232 PIB

Drug: GSK2838232 IR1

Drug: GSK2838232 IR2

Drug: Placebo PIB

Drug: Ritonavir

Enrollment:

Primary completion date:

2016-06-12

Observational study model:

Not applicable

Time perspective:

Not applicable

Clinical publications:

Johnson, M; Jewell RC; Peppercorn, A; Gould E; Xu, J; Lou, Y; Davies, M; Baldwin, S; Tenorio, A; Burke, M; Jeffrey J and Johns, B . The Safety, Tolerability, and Pharmacokinetic Profile of GSK2838232, a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects . Pharmacol Res Perspect. 2018 DOI: 10.1002/prp2.408

Medical condition

Infection, Human Immunodeficiency Virus

Product

GSK2838232, ritonavir

Collaborators

Not applicable

Study date(s)

March 2016 to December 2016

Type

Interventional

Phase

Participation criteria

Sex

Female & Male

Age

18 - 55 years

Accepts healthy volunteers

Yes

Age: Between 18 and 55 years of age inclusive, at the time of signing the informed consent.
Healthy as determined by the Investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.

Alanine aminotransferase and bilirubin >1.0* upper limit of normal (ULN).
Current or chronic history of liver disease, or known hepatic or biliary abnormalities.

Inclusion and exclusion criteria

Inclusion criteria:

Age: Between 18 and 55 years of age inclusive, at the time of signing the informed consent.
Healthy as determined by the Investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, and outside the reference range for the population being studied, may be included only if the Investigator in consultation with the Medical Monitor, if required, agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
A creatinine clearance (CLcr) >80milliliter/minute (mL/min) as determined by Cockcroft-Gault equation CLcr (mL/min) = (140 – age) * weight (Wt) / (72 * serum creatinine [Scr]) (times 0.85 if female) where age is in years, Wt is in kilogram (kg), and Scr is in units of milligram / decilitre (mg/dL);.
Body weight >= 50.0 kg (110 pounds [lbs.]) for men and >= 45.0kg (99lbs) for women and body mass index (BMI)
Male or females of non-reproductive potential: A female subject is eligible to participate if she is not pregnant [as confirmed by a negative serum human chorionic gonadotrophin (hCG) test], not lactating, and of non-reproductive potential which is defined as: Pre-menopausal females with one of the following: Documented tubal ligation; Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion ; Hysterectomy; Documented Bilateral Oophorectomy Post menopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause (refer to laboratory reference ranges for confirmatory levels)]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. Male subjects with female partners of child bearing potential must comply with the following contraception requirements from the time of first dose of study medication until one week after the last dose of study medication. Vasectomy with documentation of azoospermia, or Male condom plus partner use of one of the contraceptive options following: Contraceptive subdermal implant that meets the standard operating procedure (SOP) effectiveness criteria including a <1% rate of failure per year, as stated in the product label; Intrauterine device or intrauterine system that meets the SOP effectiveness criteria including a <1% rate of failure per year, as stated in the product label; Oral Contraceptive, either combined or progestogen alone. Injectable progestogen; Contraceptive vaginal ring; Percutaneous contraceptive patches. These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label. The Investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.
Capable of giving signed informed consent as described in Study protocol which includes compliance with the requirements and restrictions listed in the consent form and in protocol.

Exclusion criteria:

Alanine aminotransferase and bilirubin >1.0* upper limit of normal (ULN).
Current or chronic history of liver disease, or known hepatic or biliary abnormalities.
Subjects who have asthma or a history of asthma.
Medical history of cardiac arrhythmias or cardiac disease or a family and personal history of long QT syndrome
Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John’s Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GlaxoSmithKline (GSK) Medical Monitor, the medication will not interfere with the study procedures or compromise subject safety
History of regular alcohol consumption within 6 months of the study defined as: For US sites: an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 grams (g) of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150mL) of wine or 1.5 ounces (45mL) of 80 proof distilled spirits.
Regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation
Presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment.
Screening or baseline cardiac troponin I greater than the 99% cut-off (>.045 nanograms/mL by the Dimension Vista Cardiac troponin assay) for a given assay.
A positive pre-study drug/alcohol screen.
A positive test for HIV antibody.
Where participation in the study would result in donation of blood or blood products in excess of 500mL within 56 days.
The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
Exclusion Criteria for 48-Hour Screening Holter: Any symptomatic arrhythmia (except isolated extra systoles). Sustained cardiac arrhythmias (such as atrial fibrillation or flutter, supraventricular tachycardia (>=10 consecutive beats), complete heart block). Non-sustained or sustained ventricular tachycardia (defined as >= 3 consecutive ventricular ectopic beats). Any conduction abnormality (including but not specific to left or right incomplete or complete bundle branch block, atrioventricular (AV) block [2nd degree or higher], Wolf Parkinson White (WPW) syndrome etc.). Sinus Pauses > 3 seconds. 300 or more supraventricular ectopic beats in 24 hours. 250 or more ventricular ectopic beats in 24 hours.
Any clinically significant abnormal echocardiogram finding. Abnormal echocardiogram findings should be discussed with the Medical Monitor prior to enrolment.
Exclusion criteria for screening ECG (a single repeat is allowed for eligibility determination): Heart rate for Males <45 and >100 beats per minute (bpm), for females <50 and >100bpm PR Interval <120 and >220 millisecond (msec) QRS duration <70 and >120msec QT interval corrected (Fridericia’s) >450msec

Trial location(s)

Location

Status

Location

GSK Investigational Site

Baltimore, Maryland, United States, 21225

Status

Study Complete

Study documents

Clinical study report

Available language(s): English

Download document(s)

Protocol

Available language(s): English

Download document(s)

Scientific result summary

Available language(s): English

Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status

Study complete

Actual primary completion date

2016-06-12

Actual study completion date

2016-06-12

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information

Not applicable

Participate in clinical trial

Access to clinical trial data by researchers

Visit website